Summary & Overview
HCPCS C9030: Injection, copanlisib, 1 mg
HCPCS Level II code C9030 denotes the injection of copanlisib, billed per 1 mg unit. Copanlisib is an intravenous kinase inhibitor used in oncology care for select hematologic malignancies and is typically administered in hospital outpatient departments or infusion centers. Nationally, accurate coding for high-cost oncology injectables like copanlisib affects claims processing, utilization tracking, and payer coverage determinations.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for C9030, common billing considerations for parenteral oncology drugs, and what to expect in payer coverage patterns. The publication presents national benchmarks where available, summarizes relevant policy updates affecting HCPCS Level II drug billing, and outlines typical service-line implications for hospital outpatient and infusion center operations.
This summary is intended to inform billing staff, revenue cycle leaders, and policy analysts about the code's clinical purpose, typical settings of care, and the scope of payers covered in the discussion.
Billing Code Overview
HCPCS Level II code C9030 represents an injection of copanlisib, with the unit defined as 1 mg. This code describes a drug administration service for a targeted kinase inhibitor used in oncology settings.
Service Type: Parenteral drug administration (intravenous infusion or injection)
Typical Site of Service: Hospital outpatient department or infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory indolent B‑cell non‑Hodgkin lymphoma or follicular lymphoma for whom targeted kinase therapy is indicated. The patient presents to the outpatient oncology infusion clinic for scheduled intravenous administration of C9030 (copanlisib) dosed per weight or body surface area according to oncology protocols. Prior to infusion, oncology nursing completes pre‑infusion assessment including vitals, laboratory review (CBC, CMP, glucose), and verification of diagnosis and consent. The pharmacy compounds C9030 per concentration and sterility standards and delivers the labeled syringe or infusion bag to the clinic. During infusion, nursing monitors for infusion reactions, hyperglycemia, hypertension, and other adverse effects; orders may include short‑interval blood pressure and glucose checks. Post‑infusion, the clinician documents drug administration using C9030 with appropriate units (1 mg increments), records lot number and expiration, and schedules follow‑up visits and laboratory monitoring. Typical sites of service are outpatient hospital infusion centers or physician office infusion suites where parenteral antineoplastic agents are administered.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
24 |